Conditions: Parkinson Disease
Keywords: ropinirole IR efficacy safety open-label long term safety; REQUIP ropinirole XL ropinirole CR Parkinson's disease
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 76
Healthy volunteers: no

Brief summary:
The purpose of this study is to obtain information on the long-term safety, tolerability, and therapeutic benefit of extended release ropinirole XL, and to provide a mechanism for patients who participated in either Study 167 or Study 164 to continue receiving ropinirole XL if they chose to do so.

Detailed description:

Arms:
arm 1: Open label medication - Ropinirole CR

Interventions: intervention 1: Ropinirole XL (formerly CR)
Intervention descriptions: intervention 1: Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.

Protocol document: